A fledgling biopharma company with heavy hedge fund backing is seemingly moving forward with its initial public offering, despite the stock market’s sharp selloff and overall volatility and growing concern that the Covid-19 virus is spreading throughout the United States.
On Friday Renaissance Capital, an IPO research specialist, said in a report that as many as 20 IPOs have been delayed due to the coronavirus.
Zentalis
